Today, only people with high levels of cholesterol are prescribed cholesterol-lowering drugs, known as statins.
Nearly 18,000 people in 26 countries, including 7,000 women and nearly 5,000 minorities, participated in the clinical trial, the results of which were published in The New England Journal of Medicine.
All had very good cholesterol levels, with average LDL -- or "bad" cholesterol -- levels of 108 and average HDL --or "good" cholesterol -- levels of 49.
However, each participant had elevated levels of "high-sensitivity C-reactive protein" or hs-CRP -- a marker that indicates inflammation in the body and can contribute to coronary heart disease, the No. 1 killer of men and women in the United States.
Under the current guidelines set for lowering cholesterol levels, none of the participants would have qualified for taking statins.
In the study, the participants took 20 milligrams of the drug Rosuvastatin -- commercially known as Crestor -- or a placebo pill.
The maker of Crestor, AstraZeneca, funded the study.
'Business' 카테고리의 다른 글
RPT-Wall St Wk Ahead: Stocks eye retail data, Treasury pick (0) | 2008.11.10 |
---|---|
China okays $586 bln spending plan to bolster growth (0) | 2008.11.10 |
November Layoffs Hit Wide (0) | 2008.11.10 |
Issue: Getting Nestlé Waters' Green Story Out (0) | 2008.11.09 |
Event Planning Takes a Hit Amid Bleak 2009 Outlook (0) | 2008.11.09 |